Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[The PROVE IT-TIMI-22 study or the biter being bit].

C Berna1, A F Junod, I Peytremann-Bridevaux

  • 1Service de Medecine Interne Générale, Département de Médecine Interne, HUG, 1211 Genève. chantal.berna@hcuge.ch

Revue Medicale Suisse
|May 19, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Opioid analgesic effects on subjective well-being in the operating theatre.

Anaesthesia·2023
Same author

Capacity Building in Sub-Saharan Africa as Part of the INTENSE-TBM Project During the COVID-19 Pandemic.

Infectious diseases and therapy·2022
Same author

Understanding and restoring dopaminergic function in fibromyalgia patients using a mindfulness-based psychological intervention: a [18F]-DOPA PET study. Study protocol for the FIBRODOPA study-a randomized controlled trial.

Trials·2022
Same author

Participation, retention and uptake in a multicentre pre-exposure prophylaxis cohort using online, smartphone-compatible data collection.

HIV medicine·2021
Same author

Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort Study.

HIV medicine·2021
Same author

How helpful are the European AIDS Clinical Society cognitive screening questions in predicting cognitive impairment in an aging, well-treated HIV-positive population?

HIV medicine·2019
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

[Erythema multiforme : target deciphering].

Revue medicale suisse·2026
See all related articles

High-dose atorvastatin demonstrated superior LDL-cholesterol reduction and improved clinical outcomes compared to pravastatin in early secondary prevention. However, cautious use of high-dose atorvastatin in all coronary heart disease patients is recommended.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Research

Background:

  • Statins are crucial for secondary prevention in coronary heart disease (CHD).
  • Current guidelines recommend statin therapy even for patients with normal cholesterol levels.
  • Optimal statin choice and dosage for secondary prevention remain unclear.

Purpose of the Study:

  • To critically review the PROVE IT-TIMI-22 study comparing high-dose atorvastatin with pravastatin.
  • To evaluate the efficacy of intensive statin therapy in early secondary prevention.

Main Methods:

  • The PROVE IT-TIMI-22 study compared 80 mg of atorvastatin daily versus 40 mg of pravastatin daily.
  • The study focused on patients in the early stages of secondary prevention after CHD events.

Related Experiment Videos

Main Results:

  • High-dose atorvastatin significantly reduced LDL-cholesterol levels more effectively than pravastatin.
  • Intensive atorvastatin treatment showed a more favorable effect on a composite clinical outcome score.

Conclusions:

  • Intensive statin therapy with high-dose atorvastatin appears more effective in early secondary prevention.
  • A cautious approach is advised regarding the widespread use of high-dose atorvastatin in all CHD patients.